Skip to main content
Top
Published in: Diabetes Therapy 3/2016

Open Access 01-09-2016 | PRACTICAL APPROACH

A Practical Approach to Gastrointestinal Complications of Diabetes

Author: Abigail Maisey

Published in: Diabetes Therapy | Issue 3/2016

Login to get access

Abstract

Gastrointestinal symptoms occur frequently among people with diabetes mellitus and are associated with considerable morbidity. Enteropathy, or large bowel dysfunction, includes constipation, diarrhea and fecal incontinence, and is particularly disturbing for many patients. The pathogenesis of diabetic enteropathy is complex, primarily related to gastrointestinal autonomic dysfunction and etiologically associated with chronic hyperglycemia and diabetes duration. Since there are many other non-iatrogenic and iatrogenic causes of the cardinal symptoms of large bowel dysfunction, patients suspected of having diabetic enteropathy require detailed evaluation. The management of patients with diabetic enteropathy is challenging, and often requires a multidisciplinary approach focusing on a combination of symptom mitigation and glycemic control.
Literature
1.
go back to reference Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15000 adults. Arch Intern Med. 2001;161:1989–96.PubMedCrossRef Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15000 adults. Arch Intern Med. 2001;161:1989–96.PubMedCrossRef
2.
go back to reference Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6(6):417–23.PubMedCrossRef Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6(6):417–23.PubMedCrossRef
3.
go back to reference Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2007;1:CD005166.PubMed Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2007;1:CD005166.PubMed
4.
go back to reference Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371–81.PubMedCrossRef Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371–81.PubMedCrossRef
5.
go back to reference Boaz M, Kislov J, Dickman R, Wainstein J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J Diabetes Complicat. 2011;25(5):325–8.PubMedCrossRef Boaz M, Kislov J, Dickman R, Wainstein J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J Diabetes Complicat. 2011;25(5):325–8.PubMedCrossRef
6.
go back to reference Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–622.PubMedCrossRef Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–622.PubMedCrossRef
8.
go back to reference Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64(11):1181–96.PubMedCrossRef Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64(11):1181–96.PubMedCrossRef
9.
go back to reference Consoli A. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–18.PubMedCrossRef Consoli A. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–18.PubMedCrossRef
11.
go back to reference Pimentel M. Review of rifaximine as treatment for small intestinal bacterial overgrowth and irritable bowel syndrome. Expert Opin Investig Drugs. 2009;18:349–58. Pimentel M. Review of rifaximine as treatment for small intestinal bacterial overgrowth and irritable bowel syndrome. Expert Opin Investig Drugs. 2009;18:349–58.
12.
go back to reference Russo A, Botten R, Kong MF, Chapman IM, Fraser RJ, Horowitz M, Sun WM. Effects of acute hyperglycaemia on anorectal motor and sensory function in diabetes mellitus. Diabet Med. 2004;21(2):176–82.PubMedCrossRef Russo A, Botten R, Kong MF, Chapman IM, Fraser RJ, Horowitz M, Sun WM. Effects of acute hyperglycaemia on anorectal motor and sensory function in diabetes mellitus. Diabet Med. 2004;21(2):176–82.PubMedCrossRef
13.
go back to reference Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6:417–23.PubMedCrossRef Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6:417–23.PubMedCrossRef
14.
go back to reference Jung HK, Kim DY, Moon IH, Hong YS. Colonic transit time in diabetic patients—comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J. 2003;44(2):265–72.PubMedCrossRef Jung HK, Kim DY, Moon IH, Hong YS. Colonic transit time in diabetic patients—comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J. 2003;44(2):265–72.PubMedCrossRef
15.
go back to reference Chandran M, Chu NV, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 2003;3(1):43–8.PubMedCrossRef Chandran M, Chu NV, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 2003;3(1):43–8.PubMedCrossRef
16.
go back to reference Ohlsson B, Melander O, Thorsson O, Olsson R, Ekberg O, Sundkvist G. Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis. Diabetologia. 2006;49(9):2010–4.PubMedCrossRef Ohlsson B, Melander O, Thorsson O, Olsson R, Ekberg O, Sundkvist G. Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis. Diabetologia. 2006;49(9):2010–4.PubMedCrossRef
17.
go back to reference Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70.PubMedCrossRef Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70.PubMedCrossRef
19.
go back to reference Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411.PubMedCrossRef Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411.PubMedCrossRef
20.
go back to reference Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834–8.PubMedPubMedCentralCrossRef Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834–8.PubMedPubMedCentralCrossRef
21.
go back to reference Ding X, Lu CY, Liu CA, Shi YJ. Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. Hepatobilliary Panceat Dis Int. 2005;4(2):295–8. Ding X, Lu CY, Liu CA, Shi YJ. Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. Hepatobilliary Panceat Dis Int. 2005;4(2):295–8.
22.
go back to reference Frossard JL, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. World J Gastroenterol. 2009;15(42):5260–5.PubMedPubMedCentralCrossRef Frossard JL, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. World J Gastroenterol. 2009;15(42):5260–5.PubMedPubMedCentralCrossRef
23.
go back to reference Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, et al. Development and validation of the diabetes bowel symptom questionnaire. Aliment Pharmacol Ther. 2003;17(9):1179–87.PubMedCrossRef Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, et al. Development and validation of the diabetes bowel symptom questionnaire. Aliment Pharmacol Ther. 2003;17(9):1179–87.PubMedCrossRef
24.
go back to reference Gatopoulou A, Papanas N, Maltezos E. Diabetic gastrointestinal autonomic neuropathy: current status and new achievements for everyday clinical practice. Eur J Intern Med. 2012;23(6):499–505. Gatopoulou A, Papanas N, Maltezos E. Diabetic gastrointestinal autonomic neuropathy: current status and new achievements for everyday clinical practice. Eur J Intern Med. 2012;23(6):499–505.
25.
go back to reference Ulahallanan TJ, Amaratunga A. Successful treatment of diabetic autonomic diarrhoea with monthly subcutaneous lanreotide. Pract Diabetes Int. 2009;26(8):326–328i.CrossRef Ulahallanan TJ, Amaratunga A. Successful treatment of diabetic autonomic diarrhoea with monthly subcutaneous lanreotide. Pract Diabetes Int. 2009;26(8):326–328i.CrossRef
26.
go back to reference Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol (NY). 2010;6(6):1–16. Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol (NY). 2010;6(6):1–16.
Metadata
Title
A Practical Approach to Gastrointestinal Complications of Diabetes
Author
Abigail Maisey
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 3/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-016-0182-y

Other articles of this Issue 3/2016

Diabetes Therapy 3/2016 Go to the issue